Dosing typically starts lower (0.25-0.5mg) with slower titration due to generally smaller body mass
A person cannot take part in the program if they are already receiving GLP-1 medications through their Medicare Part D drug plan to treat type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease
Roughly 6% are currently using one, according to KFF
Abstract Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well tolerated, but rare serious complications may occur in some patients receiving VPA chronically, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity (VHT) and VPA-induced hyperammonaemic encephalopathy (VHE)
These natural strategies are safer, sustainable and proven to enhance the same anabolic pathways that synthetic peptides target, without legal or long-term health concerns
doi:10.1016/j.iac.2018.04.003 Sperr WR, Jordan JH, Fiegl M, et al